SPX4,153.82+95.98 2.37%
DIA331.69+5.24 1.61%
IXIC12,119.46+378.81 3.23%

Bioventus Agrees To Nationwide Contract With Cigna Commercial Plans For DUROLANE And GELSYN-3 For Knee Osteoarthritis; No Terms Disclosed

Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, has agreed to a nationwide contract with Cigna® commercial plans. Beginning July

Benzinga · 05/02/2022 07:10

Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, has agreed to a nationwide contract with Cigna® commercial plans. Beginning July 1, 2022, Cigna® commercial plan members will have access to both DUROLANE and GELSYN-3, to treat knee osteoarthritis (OA) pain. DUROLANE, is a single-injection and GELSYN-3, is a three-injection hyaluronic acid (HA)-based joint-fluid treatment for patients. Durolane will be exclusive to all Cigna patients while Gelsyn-3 will be one of two multi-injection HA products under contract.
 

OA involves the breakdown, or degeneration, of cartilage and the synovial fluid that cushions and lubricates joint tissues. Injection treatments of HA-based products, such as DUROLANE and GELSYN-3, help manage knee OA pain.

"We are pleased and excited DUROLANE and GELSYN-3 are among the preferred options available to Cigna® members and physicians," said Tim Donovan, Vice President of Market Access & Health Economics for Bioventus. "Both now have access to two safe HA products that are proven to provide relief from knee OA pain."